Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Unión Europea - español - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazol - schizophrenia; bipolar disorder - psicolépticos - aripiprazol mylan pharma está indicado para el tratamiento de la esquizofrenia en adultos y en adolescentes de 15 años en adelante. aripiprazole mylan pharma está indicado para el tratamiento de moderada a severa episodios maníacos en el trastorno bipolar i y para la prevención de un nuevo episodio maníaco en los adultos que experimentaron predominantemente maníacos y episodios de cuyos episodios maníacos respondió a aripiprazole tratamiento. aripiprazole mylan pharma está indicado para el tratamiento de hasta 12 semanas de moderada a severa episodios maníacos en el trastorno bipolar i en adolescentes de 13 años de edad y mayores.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Unión Europea - español - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - besilato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). elevación del segmento st infarto agudo de miocardio, en combinación con aas en los pacientes tratados médicamente elegibles para la terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para más información, por favor refiérase a la sección 5.

DOXAZOSINA VIATRIS PHARMACEUTICALS 4 MG COMPRIMIDOS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

doxazosina viatris pharmaceuticals 4 mg comprimidos efg

viatris limited - doxazosina mesilato - comprimido - 4 mg - doxazosina mesilato 4 mg - doxazosina

Pirfenidone Viatris Unión Europea - español - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - la pirfenidona - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - inmunosupresores - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Unión Europea - español - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

AMOXICILINA/ ACIDO CLAVULANICO VIATRIS 875/125 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

amoxicilina/ acido clavulanico viatris 875/125 mg comprimidos recubiertos con pelicula efg

viatris pharmaceuticals, s.l.u. - amoxicilina trihidrato; clavulanato potasio - comprimido recubierto con pelÍcula - 875 mg/125 mg - amoxicilina trihidrato 875 mg; clavulanato potasio 125 mg - amoxicilina e inhibidores de la betalactamasa

ACIDO ACETILSALICILICO VIATRIS 100 MG COMPRIMIDOS GASTRORRESISTENTES España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

acido acetilsalicilico viatris 100 mg comprimidos gastrorresistentes

viatris limited - acetilsalicilico acido - comprimido gastrorresistente - 100 mg - acetilsalicilico acido 100 mg - Ácido acetilsalicílico

PANTOPRAZOL VIATRIS 20 MG COMPRIMIDOS GASTRORRESISTENTES EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pantoprazol viatris 20 mg comprimidos gastrorresistentes efg

viatris limited - pantoprazol sodico - comprimido gastrorresistente - 20 mg - pantoprazol sodico 20 mg - inhibidores de la bomba de protones

PANTOPRAZOL VIATRIS 40 MG COMPRIMIDOS GASTRORRESISTENTES EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

pantoprazol viatris 40 mg comprimidos gastrorresistentes efg

viatris limited - pantoprazol sodico - comprimido gastrorresistente - 40 mg - pantoprazol sodico 40 mg - inhibidores de la bomba de protones